Pravastatin in food, not water, hits target levels in cockatiels

A new study in the American Journal of Veterinary Research reports that oral pravastatin achieved target plasma concentrations in cockatiels when administered in food, but not when provided in drinking water. The work focused on a basic but clinically important question for avian medicine: whether a statin can be delivered in a way that reliably produces blood levels likely to be therapeutically useful in a small psittacine species. (pubmed.ncbi.nlm.nih.gov)

The study builds on a broader effort to improve medical management of avian atherosclerosis and dyslipidemia, conditions that are well recognized in captive parrots but still difficult to diagnose and treat. UC Davis researchers have been active in that area, including projects on atherosclerosis imaging in parrots and earlier pharmacokinetic work showing that single-dose oral atorvastatin produced a favorable profile in cockatiels. More recently, related research has also examined lipid-associated interventions in cockatiels, including deslorelin’s effects on blood lipids and steroid hormones. (czar.vetmed.ucdavis.edu)

According to the abstract provided by the journal, the pravastatin study ran from May 5 through July 25, 2025. Seven cockatiels received a 0.4-mg/mL pravastatin solution in drinking water, while seven others received a 0.2-mg/g food mixture. The water preparation was reconstituted daily, and the food mixture was prepared once and refilled as needed. Blood samples were collected at 48, 52, and 56 hours to assess whether the birds reached target plasma concentrations over the three-day dosing period. The headline finding was straightforward: administration in food reached target concentrations, while administration in water did not. (pubmed.ncbi.nlm.nih.gov)

That result fits with a familiar challenge in bird medicine. In companion birds, voluntary water intake can fluctuate substantially with diet, stress, environment, and individual behavior, which makes water-based dosing less predictable. By contrast, food-based administration may offer tighter control when a bird reliably consumes a known ration. While this study did not establish clinical efficacy against atherosclerosis, it does help narrow the delivery strategy for future trials and for carefully selected off-label clinical use. That inference is supported by the study design and by broader avian medicine guidance stressing how nutrition and feeding behavior shape metabolic disease risk in psittacines. (pubmed.ncbi.nlm.nih.gov)

Outside commentary specific to this paper appears limited so far, but the broader field has been pointing in the same direction. Reviews and reference data in psittacine medicine describe atherosclerosis as common in captive parrots and linked to diet, age, body condition, and species differences. UC Davis’s Companion Zoological Animal Research laboratory has also highlighted the lack of good diagnostic and treatment tools for avian atherosclerosis, underscoring why incremental pharmacokinetic studies like this one matter. (pmc.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, especially avian and exotics clinicians, this is a methods paper with practical implications. If pravastatin is going to be evaluated further in cockatiels or extrapolated cautiously to other psittacines, medicated food now looks like the more credible administration route than drinking water. That could influence how clinicians think about adherence, compounding, pet parent instructions, and monitoring in birds with suspected lipid disorders or atherosclerotic disease. It also reinforces a larger point: pharmacokinetic feasibility in avian patients often depends on husbandry realities as much as on the molecule itself. (pubmed.ncbi.nlm.nih.gov)

The study also lands in a clinical landscape where diet remains foundational. Seed-heavy feeding patterns are still associated with obesity, dyslipidemia, hepatic disease, and atherosclerosis in pet birds, so any future statin use is likely to sit alongside, not replace, nutritional correction and broader case management. For veterinarians, that means the most immediate relevance may be in protocol design and client communication rather than a near-term change in standard of care. (msdvetmanual.com)

What to watch: The next steps are likely to be longer-duration studies that test safety, effects on cholesterol or lipoprotein markers, and ultimately whether pravastatin changes imaging findings or clinical outcomes in birds with naturally occurring or experimental atherosclerosis. Until then, this study is best read as a useful pharmacology signal: in cockatiels, food worked, water didn’t. (czar.vetmed.ucdavis.edu)